Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HZ-J001
- Development stage
- Unknown
- Lead developer
- Hubei Renfu Chengtian Pharmaceutical
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
HZ-J001 is an investigational small molecule topical cream developed by Wuhan Humanwell Hi-Tech Industry for the treatment of vitiligo. Vitiligo is a chronic skin condition characterized by the loss of pigment-producing melanocytes, resulting in depigmented white patches on the skin. As of mid-2025, HZ-J001 has progressed into Phase II clinical trials in China. While the specific molecular target and mechanism of action have not been publicly disclosed by the developer, the drug is being evaluated for its ability to promote repigmentation or stabilize disease progression when applied topically to affected areas.
- Other names
- HZ-J001 creamHZ-J-001 creamHZ-J 001 cream
Beyond the preview
Go deeper on HZ-J001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HZ-J001.